An institutional investor required support in understanding current and future market dynamics within the competitive and rapidly expanding PARP inhibitor space in order to inform investment decisions.
Shift Health’s Role
Working under tight timelines, Shift Health examined the evolving scientific and clinical rationale of PARP inhibition in ovarian, breast, prostate and colon cancers. We also analyzed market trends, the competitive landscape of existing and pipeline competitors, regulatory trends, and pricing and reimbursement dynamics in major markets. Building on this landscape assessment, we identified and characterized key risks associated with investments in the PARP inhibitor space.
Shift Health’s timely report provided a strong evidence base that guided the client’s investment decisions in the PARP inhibitor space.